Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 3Phase 1/2 3Phase NA 2Phase 2/3 1Phase 1 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2

Conditions

Urinary Bladder Neoplasms 2Ureteral Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1

Interventions

pembrolizumab 222Carboplatin 215Cisplatin 203Paclitaxel 181Gemcitabine 148Docetaxel 126Capecitabine 114Cyclophosphamide 102Pemetrexed 100Dexamethasone 100Specimen Handling 99Magnetic Resonance Spectroscopy 97Oxaliplatin 96Radiotherapy 94Doxorubicin 91Fluorouracil 88Bevacizumab 84Leucovorin 73Nivolumab 72Rituximab 71Vincristine 68durvalumab 65Lenalidomide 64Radiation 62atezolizumab 61Irinotecan 61Etoposide 60130-nm albumin-bound paclitaxel 58Prednisone 55Letrozole 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Cystoscopy × 1 year × Clear all
NCT07000084 2026-06-02

GAIN-BCG

Alliance for Clinical Trials in Oncology

Phase 3 Recruiting
330 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT03244384 2026-05-29

AMBASSADOR

National Cancer Institute (NCI)

Phase 3 Active not recruiting
739 enrolled

Ureteral Neoplasms

NCT03775265 2026-05-29

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
475 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡